Idana | Updates

By Lucas Spohn

Idana Launches Marketing and Sales Campaign


Dear Companists,

Our minimal viable product has grown into a software solution that satisfies even demanding users: A modern design, intuitive user interface, and the link to all common medical information systems via GDT interface make Idana a powerful tool for physicians’ daily use.  

Now it’s time to bring our product to doctors. Therefore, we launched our marketing and sales campaign this week: We will present the challenges (and chances) associated with the sale of Idana and introduce you to our sales and marketing team in this update.


Challenge eHealth: Why things are sometimes more difficult for pioneers

Idana is an innovative product that is completely new to the German market in this form. Comparable systems gather data for research or offer digital educational forms. One would think that market penetration would be easy when there are no national and very few international competitors. However, sometimes things are more difficult for pioneers.

When software developers, who improve or advance existing solutions, address their customers, these usually already have an understanding of what to expect from the product. This simplifies the marketing and sales team’s work considerably: They already know who their potential customers are and how best to reach them.

It’s a bit different for Idana: Although personal experience and thorough market research have given us in-depth knowledge of clinics and doctor’s offices, physicians usually are unaware that software can support them in the routine process of anamnesis. Although every doctor has to consider which office management system he or she wants to use and actively looks for a suitable product, we still need to create awareness that Idana can truly make a difference in daily procedures. Our first customers will be pioneers – the task now is to find them and be sought out by them.


Kick-off meeting sales: Combining forces for market penetration

The writer Ralph Waldo Emerson once said that “every revolution was first a thought in one man’s mind.” Our revolution of the anamnesis process has successfully navigated this initial phase, now it’s time to transfer the thought to the minds of its protagonists.

In cooperation with our experienced sales experts Claus and Lilian, our marketing & sales manager, our team completed intensive coaching this week. We are now ready to expand our customer base and inspire the doctors of Idana with new product brochures.


Idana - Marketing Team


We were able to strengthen this motivated team thanks to your support, dear Companists. The mindset is right, the marketing and sales strategy is sound, and we firmly believe: We can do it!


Best greetings from Freiburg,
Lucas Spohn


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 500,000




22.58 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors

0800 - 100 267 0 (DE)
0800 - 100 267(AT / CH)

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of Idana.
Already registered?    Log in